MacroGenics Inc reports results for the quarter ended June 30 - Earnings Summary

MacroGenics

13/08/2026 22:10

MacroGenics Inc MGNX.OQ reported quarterly adjusted earnings of $1.14​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -57 cents.  The mean expectation of seven analysts for the quarter was for a loss of 13 cents per share. Wall Street expected results to range from -70 cents to $1.71 per share.
Revenue rose 47.6% to $32.83 million from a year ago; analysts expected $67.46 million. 
MacroGenics Inc's reported EPS for the quarter was 31 cents​.
The company reported quarterly net income of $19.52 million.
MacroGenics Inc shares had fallen by 13.0% this quarter and gained 149.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 61.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for MacroGenics Inc is $7.00, about 42.6% above its last closing price of $4.02
This summary was machine generated from LSEG data August 13 at 09:10 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.13
1.14
Beat
Mar. 31 2026 
-0.57
-0.58
Missed
Dec. 31 2025 
-0.29
-0.23
Beat
Sep. 30 2025 
-0.49
0.27
Beat